Suicide gene therapy for human T cell mediated graft versus host disease in a murine xenograft model  by Nervi, B. et al.
131
IRRADIATION INFLUENCES ENDOTHELIAL CELL FUNCTION IN VITRO
AND IN VIVO: A POSSIBLE ROLE FOR IP10
Cannella, L.; Laylor, R.; Marelli-Berg, F.; Dazzi, F. Department of
Immunology, Imperial College, London, United Kingdom.
The cytokine storm induced by the pre-transplant conditioning
regimen, plays a major role in the development of graft-versus-host
disease (GVHD) by enhancing antigen presentation and recruiting
donor T cells to the tissues. Some of the cytokines implicated in
GVHD also activate vascular endothelium and might inﬂuence
lymphocyte trafﬁcking. We hypothesised that in addition, endo-
thelial cells (EC) irradiation contributes to their activation thus
enhancing leukocyte trafﬁcking. T cell migration through irradi-
ated or non irradiated lung-derived endothelial cell (EC) mono-
layer was measured at various intervals. We observed that, inde-
pendently of the dose used, irradiation signiﬁcantly increased the
proportion of migrating T cells at each time point. This effect
could either be due to cytoskeletal rearrangements and/or to sol-
uble factors induced by irradiation. Irradiation induced in the EC
a dose-dependent re-organization of actin stress ﬁbres. In addition,
supernatants obtained from irradiated endothelium induced T cell
chemotaxis in vitro. The chemotactic effect was signiﬁcantly re-
duced (51 to 63% inhibition) by the addition of an antibody
neutralizing the chemokine IP10. The migration pattern of T cells
was also investigated in an in vivo model in which CFSE labelled
donor T cells were infused in irradiated (1000 cGy) or untreated
(control) syngeneic recipients. Although the proportion of injected
T cells in the lymphoid organs was much higher in the irradiated
than in control hosts, the overall pattern of migration was similar.
The distribution of donor inﬁltrating cells was homogeneously
diffuse in the control group whilst clustered in follicles in irradiated
mice. We conclude that irradiation inﬂuences the migration of
donor T cells possibly via an increased production of IP10 by EC.
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TWICE-DAILY INTRAVENOUS BOLUS TACROLIMUS INFUSION FOR
ACUTE GRAFT-VS-HOST DISEASE PROPHYLAXIS
Hayek, F.N.1; Al-Ghawi, H.1; Allen, J.1; Baize, T.1; Mudd, L.2;
Mehta, A.2; Soni, S.1; Cheerva, A.1; Herzig, G.P.1; Herzig, R.H.1 1.
University of Louisville, James Graham Brown Cancer Center, Louis-
ville, KY; 2. University of Louisville, Department of Pediatrics, Louis-
ville, KY; 3. University of Louisville, Department of Bioinformatics &
Biostatistics, Louisville, KY.
Background: Tacrolimus (FK) is usually given as a continuous
24-hour infusion for acute graft-vs-host disease (GVH) prophylaxis
in the setting of allogeneic hematopoietic stem cell transplantation
(HSCT). Often, this schedule becomes logistically difﬁcult and
requires dedicated line and monitoring. We report our experience
with the use of twice-daily intravenous (IV) bolus injection. Pa-
tients and Methods: Between 01/00–06/04, 59 patients (pts) with
hematologic indication for allogeneic HSCT received twice-daily
FK for GVH prophylaxis. Patients were given FK at initial dose of
0.015 mg/kg IV bolus over 3 hours on day T 1 then every 12
hours. First trough level was drawn before the seventh dose on day
T 2 and then twice weekly unless clinically indicated otherwise.
Doses were adjusted for a target level of 10 ng/ml (range 5–20
ng/ml). Patients were switched to oral form when were clinically
able to tolerate it. Results: Median age was 49 years (range 19–64
y). Donors were transplanted for hematologic disorder indications.
Donor compatibility status was as follows: matched-related 38
(64.4%), matched-unrelated 10 (17%), and mismatched-related 11
(18.6%). FK was used in 2 GVH prophylaxis protocols: with
methotrexate or in combination with mycophenolate mofetil and
daclizumab. Median ﬁrst trough level was 9 ng/ml (range 2.6–
22.5). Rate of grade I or II acute GVH was 16.9%. Only one pt
developed grade III (1.7%) and no pt had grade IV. Signiﬁcant
nephrotoxicity (peak creatinine level 2 baseline or 2 mg/dl)
occurred in 16 patients (27.1%). Five of these pts (31.25%) had at
least 1 FK trough level 20 ng/ml whereas 15 of 44 patients with
normal renal function (34.1%) had such elevated levels. Severe
nephrotoxicity requiring dialysis occurred in 4 pts and only 1 of
these had elevated FK level. One pt developed HUS/TTP and had
all FK trough levels 
20 ng/ml. There were no grade 3 or 4
seizures or tremors. Median discharge day was T 19 (range
12–34). Two pts relapsed, but were alive, by day 100. Day-100
relapse-free mortality was 18.6%. Conclusion: Results of twice-
daily bolus tacrolimus compare favorably to historical safety and
efﬁcacy data of continuous infusion of FK in allogeneic HSCT.
Bolus infusion was easy to administer and adjust and did not
correlate with increased risk of nephrotoxicity. These results
should be further investigated in a prospective clinical trial.
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STEM CELL MOBILIZATION WITH NOVEL G-CSF ANALOGUES AUGMENT
NKT CELL RESTRICTED GRAFT-VERSUS-LEUKAEMIA EFFECTS
Morris, E.S.1,2; MacDonald, K.P.A.1; Rowe, V.1; Banovic, T.1; Kuns,
R.D.1; Olver, S.D.1; Kienzle, N.1; Porcelli, S.A.3; Pellicci, D.G.4;
Godfrey, D.I.4; Smyth, M.J.5; Hill, G.R.1,2 1. Queensland Institute of
Medical Research, Brisbane, Queensland, Australia; 2. Royal Brisbane
Hospital, Brisbane, Queensland, Australia; 3. Albert Einstein College of
Medicine, New York, NY; 4. University of Melbourne, Melbourne,
Victoria, Australia; 5. Peter MacCallum Cancer Centre, Melbourne,
Victoria, Australia.
We have studied the effect of stem cell mobilization with the potent
G-CSF and Flt-3 receptor agonist progenipoietin-1 (ProGP-1) on
graft-versus-leukaemia effects (GVL) in the B6 3 B6D2F1 murine
model of allogeneic stem cell transplantation (SCT). Donor pre-
treatment with ProGP-1 signiﬁcantly improved leukaemia free sur-
vival compared to G-CSF or control diluent pre-treatment (73%
versus 31% and 0% respectively; P
0.05) due to both reduced graft-
versus-host disease (GVHD) mortality (23% versus 55% and 100%
respectively; P
0.05) and prevention of leukaemic progression (4%
versus 30%, ProGP-1 versus G-CSF; P0.01). To dissect the mech-
anism responsible for the paradoxical enhancement of GVL we de-
veloped an in vivo cytotoxicity assay that reﬂects the killing of CD45.1
disparate donor versus CFSE labelled host splenocytes after SCT.
Anti-host cytotoxicity was signiﬁcantly enhanced when donors were
mobilised by ProGP-1 rather than G-CSF (cytotoxicity index 6.6 	
1.0 vs 3.1	 0.3, P0.01). We then utilized wild-type, perforin, FasL,
TNF or TRAIL deﬁcient donor grafts which were depleted of
CD4 and/or CD8 T cell subsets to study the molecular pathways
involved. The reduction in leukaemic progression in recipients of
ProGP-1 treated grafts was a consequence of a 2-fold increase in
anti-host cytotoxicity by donor CD8 T cells and was perforin-
restricted (P
0.01). ProGP-1 also prevented GVHD directed to
multiple minor histocompatibility antigens in the B63 Balb/Bmodel
despite enhancing anti-host cytotoxicity. The addition of Flt-3L to
G-CSF during stem cell mobilization or the addition of puriﬁed
CD11chi dendritic cells to G-CSF mobilized grafts failed to augment
donor anti-host cytotoxicity or further separate GVHD and GVL.
Conversely, stem cell mobilization with pegylated-G-CSF to prolong
G-CSF receptor stimulation prevented GVHD and reproduced the
augmentation of cytotoxicity seen in recipients of ProGP-1 mobilized
grafts. Mobilization with ProGP-1 signiﬁcantly increased splenic and
hepatic invariant NKT cell numbers and increased IFN- secretion
following in vitro stimulation with -GalCer analogues. Strikingly,
the augmentation of donor CD8 T cell cytotoxicity following mo-
bilization with ProGP-1 was lost whenNKTdeﬁcient (J18/) mice
were utilized as donors. Thus, enhanced G-CSF signalling by potent
G-CSF receptor agonists during stem cell mobilization augments
NKT cell dependent CD8 cytotoxicity following SCT and pro-
foundly separates GVHD and GVL.
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SUICIDE GENE THERAPY FOR HUMAN T CELL MEDIATED GRAFT VER-
SUS HOST DISEASE IN A MURINE XENOGRAFT MODEL
Nervi, B.1; Rettig, M.P.1; Ritchey, J.1; Walker, J.1; Bauer, G.1;
Herrbrich, P.E.1; Bonyhadi, M.L.2; Nolta, J.A.1; DiPersio, J.F.1 1.
Washington University School of Medicine, St. Louis, MO; 2. Xcyte
Therapies, Inc., Seattle, WA.
Graft-versus-host disease (GvHD) remains a major cause of mor-
bidity and mortality following allogeneic bone marrow transplan-
tation. We developed a novel chimeric suicide gene in which the
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extracellular and transmembrane domains of human CD34 were
fused in frame to the entire coding region of HSV-tk (CD34-tk).
In this study, we developed a new model for xenogenic GvHD
using immunodeﬁcient NOD SCID 2M null mice (2) and eval-
uated the ability of ganciclovir (GCV) to prevent GvHD after
infusion of CD34-tk-modiﬁed human T cells (Td). Sublethally
irradiated (250 cGy) 2 mice injected retro-orbitally (ro) with
human PBMCs (107T cells; n11) or human T cells (HuT; 107;
n14) had 19% HuT engraftment after 2–3 weeks with an OS of
75% and 25%, respectively, at 5 weeks (p0.006). These mice lost
20% of their body weight and had extensive HuT inﬁltration in
the spleen, liver, lung and kidney. On day 10 and before the start
of any clinical signs of GvHD, mice that went on to develop lethal
GvHD had a 10–15 fold increase in the expression of the HuT
activation markers CD25, CD30, and CD69 in blood (p
0.0005)
and tissues, and a 128-fold increase in serum levels of IFN (5150
pg/ml vs 40 pg/ml) compared to mice that did not develop GVHD.
To generate CD34-tk-modiﬁed human T cells, PBMCs were ac-
tivated with anti-CD3 and anti-CD28 mAbs immobilized on mag-
netic beads (Xcyte™ Dynabeads) in the presence of IL-2 (50
U/mL). After 2 days, cells were incubated with 293 GPG-derived
VSV-G pseudotyped CD34-tk oncoretroviral supernatants for 6 h
at 37C. Td cells were then expanded for 2 more days and isolated
by MACS (Miltineyi Biotech; Td60%). Td cells were puriﬁed to
94% by CD34 immunomagnetic selection using a VarioMACS
magnetic cell separator. Naive T cells (n2), activated non-Td T
cells (Act; n3) and Td and selected T cells (n6) were then
injected ro into 250 cGy conditioned 2 mice. Animals receiving
Td cells were then either left untreated or treated with GCV (1
mg/day, ip) from days 1–7. Mice that received naive T cells died of
lethal GvHD on day 15. Mice that received Act or Td HuT had an
average engraftment of 16% and 34%, respectively, at 3 weeks
post-infusion but did not develop GvHD. We were able to dem-
onstrate that Td T cells could be efﬁciently eliminated in vivo by
treatment with GCV. In conclusion, this xenograft model provides
a unique opportunity for preclinical testing of the CD34-tk/GCV
suicide gene system as well as other methods of GvHD control.
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HUMAN LANGERHANS CELLS IN TRANSPLANTATION: RECIPIENT
CELLS SURVIVE CONDITIONING BUT DONOR CELLS PREDOMINATE AT
DAY 100
Collin, M.P.1; Booth, T.1; Middleton, P.G.1; Jackson, G.H.1; Mackin-
non, S.2; Cook, G.3; Cavet, J.4; Wang, X.N.1; Dickinson, A.M.1 1.
University of Newcastle, Newcastle-upon-Tyne, United Kingdom; 2.
Royal Free Hospital and University College, London, United Kingdom;
3. St. James’s University Hospital, Leeds, United Kingdom; 4. Christie
Hospital, Manchester, United Kingdom.
Graft versus host disease (GvHD) is mediated by donor lympho-
cytes responding to recipient antigens. Recent murine studies have
highlighted the role of recipient antigen-presenting cells (APC) in
triggering acute GvHD. In humans, the fate of recipient APC after
transplantation is largely unknown but persistent recipient cells are
thought to increase the toxicity of early donor lymphocyte infusion
(DLI) and contribute to delayed acute GvHD after immunosup-
pression withdrawal following reduced intensity conditioning. We
have studied Langerhans Cells (LC) in human transplantation
using confocal microscopy to measure cell density in the epidermis.
We have also determined the origin of LC migrating in vitro from
epidermal sheets derived from clinical skin biopsies taken at day
100 post-transplant. In sex-mismatched donor-recipient pairs,
combined Giemsa-FISH X/Y allows precise cell identiﬁcation and
quantitation, unlike in situ techniques. We have studied 144 biop-
sies from over 50 patients conditioned with myeloablative or re-
duced intensity regimens and transplanted from related or unre-
lated donors from pretransplant to 1 year post transplant. LC
genotype has been examined at day 100 in 12 patients. Pretrans-
plant, LC density is not signiﬁcantly different to normal skin
(645 	 273 cells/mm2 vs 705 	 94 cells/mm2). At Day 0, LC
density falls to 593 	 143 cells/mm2 (p 
 0.05) but there is no
difference between myeloablative and reduced intensity condition-
ing. Alemtuzumab conditioning has no signiﬁcant impact. LC
nadir is at 3 weeks, 1 week after neutrophil nadir and 2 weeks after
monocyte nadir. Normal LC density is recovered by day 100 and
exceeds pretransplant density (822	 332 cells/mm2; p
 0.05). LC
recovered from patient biopsies at day 100 show donor predomi-
nance (95%) if the patient is fully engrafted (95% donor in
whole blood; 10/12 patients). In contrast to murine experiments,
the absence of GvHD after T cell depletion (4/12 patients) does
not confer an increased number of recipient cells. Recipient cells
are only preserved when there is signiﬁcant partial donor multi-
lineage chimaerism (2/12 patients). These results support a role for
recipient APC in early acute GvHD as more than two-thirds of
recipient cells survive conditioning. However, recipient APC do
not persist for long periods after transplantation unless there is
signiﬁcant partial chimaerism overall. The role of recipient APC
late GvHD effects must therefore be questioned.
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THE CONTRIBUTION OF CCR1 EXPRESSION ON DONOR LEUKOCYTES
TO THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEUMONIA
SYNDROME
Hildebrandt, G.C.1,2; Choi, S.2; Olkiewicz, K.M.2; Corrion, L.A.2;
Chensue, S.W.3; Liu, C.4; Cooke, K.R.2 1. Department of Hematology
and Oncology, BMT Program, University of Regensburg, Regensburg,
Germany; 2. Department of Pediatrics, University of Michigan, Ann
Arbor, MI; 3. Department of Veterans Affairs Medical Center, Ann
Arbor, MI; 4. Department of Pathology, University of Florida College of
Medicine, Gainesville, FL.
Idiopathic Pneumonia Syndrome (IPS) is a severe complication
of allogeneic (allo) bone marrow transplantation (BMT). IPS is
characterized by cellular inﬁltration into the lung that results in
altered pulmonary function and death in the majority of patients.
Leukocyte recruitment during the development of IPS is mediated
by chemokines and their receptors. Speciﬁcally, we have recently
shown an important role for CCL5 (RANTES) in the development
of lung injury following BMT. Receptors for CCL5 include both
CCR5 and CCR1. Although the absence of CCR5 expression has
been shown to worsen GVHD and IPS in some models, the role of
CCR1 in each context remains to be determined. CCR1 is ex-
pressed on a variety of cell types including Th1 lymphocytes,
monocytes and macrophages and contributes to lung injury in a
variety of non-BMT animal models. Using an established mouse
BMT system, we investigated the contribution of CCR1 to exper-
imental IPS. Lethally irradiated B6D2F1 mice received BM and T
cells from syngeneic B6D2F1 or allo B6 CCR1/ donors. Lung
injury developed between 2 and 6 weeks after allo BMT and was
associated with increases in whole lung CCR1 and CCL5 mRNA
expression. Transplantation of CCR1/ donor cells resulted in a
signiﬁcant reduction in IPS severity 6 weeks after BMT as mea-
sured by lung pathology and BAL ﬂuid cellularity, protein content
and TNF levels (Table 1) when compared to allo CCR1/
recipients. Similar differences between groups were also noted at
day 30 (data not shown). CCR1/ BMT also resulted in reduced
systemic GVHD as assessed by survival (92% vs. 50%), clinical
score (1.0	 0.3 vs. 3.0	 0.5) and intestinal injury (index at day 14:
15.8 	 1.8 vs. 23.8 	 1.0) compared to allo controls. In addition,
both splenic T cell expansion (3.7 	 0.4 vs. 9.6 	 0.9  106 cells)
and serum IFN levels (4561 	 559 vs. 10028 	 681 pg/ml) were
signiﬁcantly lower at day 7 following allo BMT with CCR1/
donor cells. In conclusion, our data demonstrate a heretofore
unknown role for CCR1 on donor leukocytes in the development
of IPS and GVHD. Improvement in lung injury observed after
CCR1/ BMT may be attributed to 1) alterations in leukocyte
recruitment to the lung and 2) modulation of donor T cell re-
sponses to host allo-antigens. These data support our previous
ﬁndings that blocking speciﬁc chemokine receptor:ligand interac-
tions may represent novel, non-cross reactive approaches to reduce
deleterious graft-versus host reactions following allo BMT.
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